Researchers from Vanderbilt-Ingram Cancer Center discovered that T-cells recognizing the cardiac antigen α-myosin are the mechanism for immunotherapy-related myocarditis.
The University of Texas MD Anderson Cancer Center and AmMax Bio, Inc. announced a worldwide exclusive license agreement and clinical trial agreement to develop and advance AmMax’s AMB-066 monoclonal antibody therapy as a first-in-class treatment option for patients with colorectal cancer and minimal residual disease as well as those with MRD in other solid tumors.
